Article

Rheumatoid Factor Variation Complicates RA Criteria

Uniform application of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis (RA) is hampered by difficulty in defining a high rheumatoid factor (RF) level because of the variation in RF levels obtained with the use of different methods.

Uniform application of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis (RA) is hampered by difficulty in defining a high rheumatoid factor (RF) level because of the variation in RF levels obtained with the use of different methods. The prognostic value of high RF level is limited compared with anti–cyclic citrullinated protein (anti-CCP) antibody positivity.

van der Linden and associates studied 972 patients in 3 cohorts for RA development and arthritis persistence. Test characteristics (eg, positive and negative likelihood ratios [LRs]) and absolute posttest changes in RA status (positive predictive value [PPV] and negative predictive value [NPV]) were determined.

The presence of anti-CCP antibody had a better balance between positive LR and negative LR and between PPV and NPV for RA development than high RF levels. Performing an anti-CCP antibody test in addition to RF level testing seemed more valuable than determining the RF level after determining the presence of anti-CCP antibodies. The association between anti-CCP antibodies and RA severity was stronger than that between high RF level and RA severity.

The authors noted that omitting RF level may improve the criteria.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.